EUVIMEDEUVIMED entdecken
Crossref

Safety, Pharmacokinetics, and Pharmacodynamics of SHR-2004, a Novel Humanized Monoclonal Antibody Targeting Factor XI, in Patients with Atrial Fibrillation: An Open-Label Phase 1b Study

Jun Jiang, Yaping Wang, Yumin Zhang, Ping Zhang, Jiahui Wu, Yang Lin, Guohai Su, Qing Wen, Jiawen Ye, Yanli Dong, Yuqi Wang, Jianan Wang

Clinical Pharmacokinetics · 30.10.2026

DOI: 10.1007/s40262-026-01720-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacokinetics, online erschienen am 30.10.2026. Verfasst von Jun Jiang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Internal Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, No. 88, Jiefang Road, Shangcheng District…. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Jiangsu Hengrui Pharmaceuticals Co., Ltd.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

SHR-2004, a humanized monoclonal antibody targeting factor XI (FXI), demonstrates potential for preventing and treating thrombotic events with reduced bleeding risk. This study evaluated the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of SHR-2004 in patients with atrial fibrillation (AF).

Methods

In this open-label dose-escalation phase 1b study, patients with AF aged ≥ 40 and < 80 years with a CHA2DS2-VASc score ≥ 1 (male) or ≥ 2 (female) were enrolled to receive six doses of SHR-2004. The primary endpoints were safety and tolerability. PK and PD parameters, including activated partial thromboplastin time (aPTT) and FXI activity, were also assessed.

Results

From 10 April 2024 to 6 May 2024, ten patients were enrolled to receive SHR-2004 (180 mg subcutaneously, every 2 weeks), with a median age of 68.0 years, and male being in the majority (9/10). The median CHA2DS2-VASc score was 2.5 (range 1–6). The trial was terminated after completion of the 180 mg cohort. SHR-2004 was well tolerated. Treatment-emergent adverse events (AEs) occurred in eight (80.0%) patients, and treatment-related AEs were reported in six (60.0%) patients. All AEs were mild or moderate. Notably, no major or clinically relevant nonmajor bleeding events were reported. Plasma exposure of SHR-2004 increased rapidly after administration and reached steady state by day 57 with the geometric mean (CV%) plasma concentration of 24,000 (26.4) ng/mL. This exposure resulted in median FXI activity after the first dose of 1.40% (IQR 1.40–1.40%). The outcomes of PD effects, FXI activity and aPTT prolongation, reached a plateau during the treatment period from day 3 to day 85 indicating that the 180 mg dosage regimen achieved and maintained therapeutic pharmacodynamic steady state.

Conclusions

Multiple subcutaneous doses of SHR-2004 were generally well tolerated in patients with AF. These preliminary findings support further clinical development of SHR-2004 in this population. Trial Registration Number Clinicaltrials.gov identifier: NCT06280768. Trial registration date: 28 February 2024

Autor:innen und Institutionen

  • Cardiovascular Internal Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, No. 88, Jiefang Road, Shangcheng District, Hangzhou, 310000, China.
  • Cardiovascular Internal Medicine, The Third Hospital of Changsha, Changsha, China.
  • Phase I Clinical Trial Laboratory, The Third Hospital of Changsha, Changsha, China.
  • Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
  • Phase I Clinical Trial Laboratory, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
  • Cardiovascular Internal Medicine, Jinan Central Hospital, Jinan, China.

Förderung

  • Jiangsu Hengrui Pharmaceuticals Co., Ltd

Zitieren

APA

Jiang, J., Wang, Y., Zhang, Y., Zhang, P., Wu, J., Lin, Y., Su, G., Wen, Q., Ye, J., Dong, Y., Wang, Y., & Wang, J. (2026). Safety, Pharmacokinetics, and Pharmacodynamics of SHR-2004, a Novel Humanized Monoclonal Antibody Targeting Factor XI, in Patients with Atrial Fibrillation: An Open-Label Phase 1b Study. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-026-01720-7

Vancouver

Jiang J, Wang Y, Zhang Y, Zhang P, Wu J, Lin Y, et al. Safety, Pharmacokinetics, and Pharmacodynamics of SHR-2004, a Novel Humanized Monoclonal Antibody Targeting Factor XI, in Patients with Atrial Fibrillation: An Open-Label Phase 1b Study. Clinical Pharmacokinetics. 2026. doi:10.1007/s40262-026-01720-7

BibTeX
@article{Jiang2026,
  author = {Jiang, Jun and Wang, Yaping and Zhang, Yumin and Zhang, Ping and Wu, Jiahui and Lin, Yang and Su, Guohai and Wen, Qing and Ye, Jiawen and Dong, Yanli and Wang, Yuqi and Wang, Jianan},
  title = {Safety, Pharmacokinetics, and Pharmacodynamics of SHR-2004, a Novel Humanized Monoclonal Antibody Targeting Factor XI, in Patients with Atrial Fibrillation: An Open-Label Phase 1b Study},
  journal = {Clinical Pharmacokinetics},
  year = {2026},
  doi = {10.1007/s40262-026-01720-7}
}
Kostenlos starten →